Midgard Science

Nona Biosciences

Cambridge, MA, United States nonabio.com From their website, Nov 2026

Work here? Claim this listing

About

Nona Biosciences develops discovery, engineering, screening, and development capabilities for antibodies, siRNA, and other next-generation modalities. It serves biopharma teams working on therapeutic candidates from early discovery through IND-enabling stages. The company describes platform technologies including Harbour Mice®, Hu-mAtrIx™, and CAR-based functional screening.

Services

  • Fully Human Antibody Discovery

    Discovery of fully human antibodies using the company's antibody platform technologies.

  • siRNA Discovery

    Discovery support for siRNA therapeutic candidates.

  • Beacon Single B Cell Screening

    Single B cell screening service using Beacon technology.

  • CAR-based Functional Screening

    Functional screening based on CAR systems for antibody and related discovery workflows.

  • Display Screening

    Display-based screening for antibody discovery and selection.

  • Hybridoma Screening

    Screening of hybridoma-derived antibody candidates.

  • Antibody Engineering Capability

    Engineering support for antibody optimization and design.

  • Bispecific/Multispecific Antibody Engineering

    Engineering services for bispecific and multispecific antibodies.

17 more services
  • Bispecific Antibody Developability Assessment
  • ADC Engineering & Conjugation
  • Toxicology and Safety Assessment
  • IND-enabling CMC
  • mRNA-LNP Delivery
  • Blood Brain Barrier Delivery
  • In Vivo CAR Delivery
  • Oligonucleotide Delivery
  • HBICE® – Bi/Multi-specific CAR-based Cell Therapy
  • Antibody Drug Conjugates
  • mRNA
  • TCR Mimic Antibody
  • siRNA Therapeutics
  • Antibody-Oligonucleotide Conjugates
  • Antibody Screening Capabilities
  • Targeted Cargo Delivery Systems
  • Integrated Idea – IND Program

Capabilities

Assays and studies
  • Antibodies
  • Rodent models
  • Bispecifics
  • ADCs
  • mRNA
  • Oligonucleotides
13 more
  • Cell therapy
  • Toxicology
  • Hybridoma
  • In vivo
  • Single B cell screening
  • CAR-based functional screening
  • Display screening
  • Hybridoma screening
  • Bispecific antibody developability assessment
  • B cell sorting
  • Functional screening
  • Developability assessment
  • Affinity prioritization
Scale and capacity
  • 140+ partners
  • 380+ projects
  • 20+ IND/Clinical Stage

Instruments and platforms

  • Beacon

Modalities and species

Modalities
  • Antibody
  • Bispecific
  • ADC
  • Oligonucleotide
  • mRNA
  • Cell therapy
  • LNP / formulation
Species and models
  • Harbour Mice® HCAb
  • Harbour Mice® H2L2
  • Mice
  • Beacon
  • Hybridoma

Industries served

  • Biopharma
  • Biotech

Details

Type
CRDMO
Based in
Cambridge, MA, United States
Serves
Global

Similar labs